GRIN Therapeutics Launches Phase 3 Beeline Study Across Europe for Radiprodil

GRIN Therapeutics, Inc., a pioneer in developing targeted therapies for serious neurodevelopmental disorders, recently announced the launch of its pivotal Phase 3 Beeline study in Europe. This significant move brings the company closer to its objective of providing effective treatments for GRIN-related neurodevelopmental disorder (GRIN-NDD).

The Beeline trial is designed as a global, registrational study aimed at examining the safety and efficacy of radiprodil, which is a selective negative allosteric modulator of the NMDA receptor's GluN2B subunit. This drug targets the direct biological causes of NMDA receptor overactivation, which is believed to contribute to the symptoms of GRIN-NDD, including severe seizures and other behavioral issues.

Dr. Bruce Leuchter, the President and CEO of GRIN Therapeutics, emphasized the importance of this trial, stating, “Expanding the Beeline study into Europe brings us closer to delivering what we hope will be the first targeted, disease-modifying therapy for patients living with this complex and life-altering condition.” His commitment reflects the dedication of the entire team to families affected by GRIN-NDD.

The initiation of this study follows promising evidence from the open-label Phase 1b/2a Honeycomb study, where radiprodil demonstrated encouraging effects on seizure frequency and overall clinical outcomes in patients with GRIN-NDD caused by gain-of-function (GoF) variants. Notably, this prior study reported a remarkable median reduction of 86% in seizure frequency for patients experiencing countable motor seizures. Observations from clinicians and caregivers indicated favorable effects on various clinical aspects, leading to the support for GRIN’s Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).

The Phase 3 Beeline study’s design incorporates insights from patients, caregivers, and healthcare professionals. It aims to assess behavioral symptoms that are meaningful to those directly affected while also allowing for the inclusion of patients with significant behavioral symptoms, regardless of seizure presence.

Notably, the study’s expansion into Europe involves multiple countries such as Belgium, France, Germany, Italy, Poland, the Netherlands, Slovenia, and Spain. These sites include established centers from previous studies and newly engaged clinical locations, ensuring effective study implementation and increased accessibility for a broader range of patients.

As the trial progresses, more European countries are anticipated to join in September 2026, which will deepen GRIN Therapeutics' efforts to expedite the development of radiprodil and make it available for families impacted by GRIN-NDD.

Families looking for more information about the study can refer to organizations like GRIN Europe (grineurope.org) and CureGRIN (curegrin.org), or contact their national advocacy groups. This access to information can enable families to make informed decisions about potential participation in ongoing clinical trials and help foster community support.

About Radiprodil

Radiprodil is currently under investigation as a potent negative allosteric modulator targeting the GluN2B subunit of the NMDA receptor. Though still in the clinical trial phase, it has gained recognition from the U.S. Food and Drug Administration (FDA) for various designations, including Breakthrough Therapy and Orphan Drug status. The Phase 3 Beeline study specifically aims to evaluate the drug's impact on key facets of GRIN-NDD, focusing on seizures and behavioral outcomes.

In addition to GRIN-related conditions, radiprodil is being studied for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II, further showcasing its potential benefits in addressing neurological disorders connected to NMDA receptor overexpression.

About GRIN Therapeutics

GRIN Therapeutics, an affiliate of Neurvati Neurosciences and part of Blackstone Life Sciences, is dedicated to finding innovative solutions for neurodevelopmental disorders. With ongoing trials and promising data, the organization remains focused on bringing hope to patients and their families through transformative therapeutic options. The company continues to explore developments for various neurodevelopmental disorders with the goal of enhancing the quality of life for those affected.

For additional insights and updates regarding GRIN Therapeutics and the Beeline study, please visit their official website or follow their press releases for real-time information on advancements in neurodevelopmental disorder treatments.